Using PET/MR to identify types of kidney tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of Fludeoxyglucose (18F) PET/MR imaging in distinguishing between aggressive and benign kidney tumors. With the rising incidence of incidental renal masses detected through imaging, the study seeks to address the issue of over-treatment by providing a more accurate diagnostic tool. Participants will include individuals with solid renal masses measuring between 2 to 7 cm, and the study will assess the imaging's ability to differentiate tumor types compared to standard radiologic scans.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with known solid (\>25% total volume enhances) renal mass
* Renal mass size measuring \>2 to ≤7 cm
* Age \>18 years
* Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

* Pregnancy
* Prior percutaneous biopsy of the renal mass
* Prior treatment of the renal mass
* Prior hemorrhage in the renal mass
* Contraindication to MRI or PET
* Renal mass not eligible for ccLS based on prior imaging (i.e., containing macroscopic fat \[classic angiomyolipoma\] or enhancing less than 25% of its volume \[considered a cystic renal mass\])
* Genetic syndrome predisposing to renal masses (e.g., VHL, BHD, TSC, etc.);
* More than 3 renal masses at time of initial diagnosis

Where it's running

• University of Texas Southwestern Medical Center
  Dallas, Texas, United States Recruiting
• The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Robert C Sibley, MD — University of Texas Southwestern Medical Center
• Study coordinator: UTSW Radiology Clinical Research Office
• Email: RCRO@utsouthwestern.edu
• Phone: 214-645-1568

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Plasma DNA Methylation to Classify Kidney Masses Before Surgery

  This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07874542

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Intensified monitoring to personalize cabozantinib dosing in advanced kidney cancer

  We will test whether closer pharmacology-based monitoring helps people with advanced kidney cancer tolerate cabozantinib better while keeping its effect against the cancer.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordenone · NCT07805122

• Who’s at high risk after RCC surgery? Real-world clues from French registry

  This study looks at real-world data from French RCC patients who had local or high-risk locally advanced disease to see how they do after surgery and how doctors decide on adjuvant treatment.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07753343

• MRI-based AI to classify and grade renal tumors

  This study tests AI methods on MRI data from adults with kidney tumors to see if they can identify tumor type and grade before surgery.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07743749

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.